Scarica l'app Stockscreener
38.30
5.77%
2.09
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
Technical Analysis: Will vTv Therapeutics Inc outperform the market in YEAR2026 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
How CRH plc stock performs during market volatility - baoquankhu1.vn
Aug Action: Does vTv Therapeutics Inc have declining or rising EPSEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Moves: Is vTv Therapeutics Inc exposed to currency risks2026 Key Highlights & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (VTVT) - Stock Traders Daily
Guidance Update: Will vTv Therapeutics Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
Published on: 2026-03-23 05:09:08 - baoquankhu1.vn
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
VTV Therapeutics (VTVT) reports $27M 2025 net loss amid cadisegliatin advancements - MSN
VTVT Forecast, Price Target & Analyst Ratings | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements - Yahoo Finance
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade - Yahoo Finance
vTv Therapeutics to Participate in the 38th Annual ROTH Conference - The Manila Times
VTv Therapeutics to Participate in the 38th Annual ROTH Conference - marketscreener.com
Biotech developing oral type 1 diabetes drug joins ROTH investor event - Stock Titan
Baker BROS. Advisors LP Has $3.46 Million Holdings in vTv Therapeutics Inc. $VTVT - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Evercore - MarketBeat
Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to "Hold" - MarketBeat
HC Wainwright Raises Earnings Estimates for vTv Therapeutics - Defense World
HC Wainwright Brokers Increase Earnings Estimates for VTVT - Defense World
HC Wainwright Forecasts Higher Earnings for vTv Therapeutics - MarketBeat
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF) - The Globe and Mail
Evercore ISI initiates vTv Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target - marketscreener.com
Evercore ISI Initiates Coverage on VTVT with Outperform Rating | VTVT Stock News - GuruFocus
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Research Analysts Set Expectations for VTVT Q1 Earnings - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving AverageShould You Sell? - MarketBeat
vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday - MarketBeat
Avoiding Lag: Real-Time Signals in (VTVT) Movement - Stock Traders Daily
BTIG Maintains Buy on vTv Therapeutics Inc (VTVT) March 11, 2026 - Meyka
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained By Investing.com - Investing.com Canada
VTVT: BTIG Reiterates Buy Rating with Unchanged Price Target | V - GuruFocus
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained - Investing.com
vTv Therapeutics 2025 – Pipeline, Clinical Trials, and Patent Portfolio Overview - Minichart
vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TipRanks
VTv Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway - TipRanks
vTv Therapeutics 2025 10-K: $0.0M Revenue, $(26.97)M Net Loss - TradingView
VTv Therapeutics: Fourth Quarter Earnings Overview - Bitget
vTv Therapeutics Inc 預計每股虧損 81 美分財報前瞻 - TradingView
VTV Therapeutics (VTVT) Quarterly & Annual Financial Results 2026News and Statistics - IndexBox
vTv Therapeutics (NASDAQ: VTVT) highlights cadisegliatin Phase 3 and new funding - Stock Titan
VTVT Stock Bolstered by Strong Financials and Strategic Advances - GuruFocus
vTv Therapeutics (VTVT) spotlights Phase 3 cadisegliatin and cash runway - Stock Titan
vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09) - TipRanks
vTv Therapeutics (VTVT) boosts cash, advances Phase 3 CATT1 trial - Stock Titan
vTv Therapeutics Q4 net loss widens on higher expenses - TradingView
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Weekly Voice
Vtv Therapeutics: Capital Efficiency and Clinical Catalysts Under Scrutiny - AD HOC NEWS
Aug Shorts: Will vTv Therapeutics Inc outperform the market in YEAREarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
How vTv Therapeutics Inc. (5VT0) stock correlates with oil marketsJuly 2025 WrapUp & Fast Entry High Yield Tips - Naître et grandir
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737 - Yahoo Finance
12 Most Promising Micro-Cap Stocks According to Analysts - Insider Monkey
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):